• Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentation
• New Phase IIIb REMIXED extension data in chronic spontaneous urticaria to provide additional efficacy and safety data for Rhapsido
• Phase II Rhapsido food allergy dose-response analysis in adults with IgE-mediated peanut allergy also to be presented

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of A